CD274 and neoplasm: In the context of the TOPACIO trial, known biomarkers of response to PARPi and immune checkpoint blockade were not associated with response to the niraparib/pembrolizumab combination; these biomarkers include tumor BRCA mutation status, homologous recombination deficiency (HRD) status (assessed by the Myriad HRD test), and PD-L1 status.